Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population

Padmavathi Devagudi; Mabu Shareef; Naser Ashraf Tadvi

doi:10.5455/njppp.2017.7.0926330092016

2025, Vol: 15, Issue: 6

15 / 6Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form

« Previous Article

Original Research
Online Published: 15 Oct 2016

Natl J Physiol Pharm Pharmacol. 2017; 7(3): 250-254

doi: 10.5455/njppp.2017.7.0926330092016

Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population

Padmavathi Devagudi, Mabu Shareef, Naser Ashraf Tadvi.

Abstract
Background: Triple therapy which includes a proton pump inhibitor (PPI) along with two antimicrobials is routinely used for the eradication of Helicobacter pylori. Multiple regimens are reported using different combinations of PPIs and antimicrobials.

Aims and Objectives: The current study is done to compare the efficacy and safety of three PPIs omeprazole, lansoprazole, and rabeprazole in combination with amoxicillin and tinidazole.

Materials and Methods: The patients were randomly assigned to receive one of the three regimens including one of the PPI with amoxicillin and tinidazole for 2 weeks followed by respective PPI once daily for 4 weeks. Follow-up visits were done at 2 and 6 weeks of the treatment. Endoscopy was done for any decrease in size of ulcer, rapid urease test, and histopathology for clearance of H. pylori.

Results: There was a significant reduction in the size of ulcer at the end of 2 weeks in all the three groups and total healing of ulcer was observed in rabeprazole group when compared to omeprazole and lansoprazole groups. H. pylori eradication as per negative urea breath test was between 85% and 94% and it was highest in rabeprazole group.

Conclusion: The three drugs were safe and equally effective in eradicating H. pylori, but rabeprazole showed earlier symptomatic relief with rapid eradication rate of H. pylori in peptic ulcer disease compared to omeprazole and lansoprazole, but it was not statistically significant. Hence, rabeprazole can be recommended to be used in PPI-triple therapy for cure of H. pylori infection in Indian population for earlier relief and better cure rates.

Key words: Helicobacter pylori; Peptic Ulcer; Rabeprazole

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Padmavathi Devagudi Articles by Mabu Shareef Articles by Naser Ashraf Tadvi
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Devagudi P, Shareef M, Tadvi NA. Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population. Natl J Physiol Pharm Pharmacol. 2017; 7(3): 250-254. doi:10.5455/njppp.2017.7.0926330092016

Web Style

Devagudi P, Shareef M, Tadvi NA. Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population. https://www.njppp.com/?mno=241646 [Access: November 01, 2025]. doi:10.5455/njppp.2017.7.0926330092016

AMA (American Medical Association) Style

Devagudi P, Shareef M, Tadvi NA. Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population. Natl J Physiol Pharm Pharmacol. 2017; 7(3): 250-254. doi:10.5455/njppp.2017.7.0926330092016

Vancouver/ICMJE Style

Devagudi P, Shareef M, Tadvi NA. Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population. Natl J Physiol Pharm Pharmacol. (2017), [cited November 01, 2025]; 7(3): 250-254. doi:10.5455/njppp.2017.7.0926330092016

Harvard Style

Devagudi, P., Shareef, . M. & Tadvi, . N. A. (2017) Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population. Natl J Physiol Pharm Pharmacol, 7 (3), 250-254. doi:10.5455/njppp.2017.7.0926330092016

Turabian Style

Devagudi, Padmavathi, Mabu Shareef, and Naser Ashraf Tadvi. 2017. Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population. National Journal of Physiology, Pharmacy and Pharmacology, 7 (3), 250-254. doi:10.5455/njppp.2017.7.0926330092016

Chicago Style

Devagudi, Padmavathi, Mabu Shareef, and Naser Ashraf Tadvi. "Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population." National Journal of Physiology, Pharmacy and Pharmacology 7 (2017), 250-254. doi:10.5455/njppp.2017.7.0926330092016

MLA (The Modern Language Association) Style

Devagudi, Padmavathi, Mabu Shareef, and Naser Ashraf Tadvi. "Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population." National Journal of Physiology, Pharmacy and Pharmacology 7.3 (2017), 250-254. Print. doi:10.5455/njppp.2017.7.0926330092016

APA (American Psychological Association) Style

Devagudi, P., Shareef, . M. & Tadvi, . N. A. (2017) Comparative study of safety and efficacy of omeprazole, lansoprazole, and rabeprazole in triple therapy for eradication of Helicobacter pylori in peptic ulcer patients in Indian population. National Journal of Physiology, Pharmacy and Pharmacology, 7 (3), 250-254. doi:10.5455/njppp.2017.7.0926330092016

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article